Selected research
Industry Research
Scopolamine Butylbromide Industry Research Report 2026
Market perspective
The global Scopolamine Butylbromide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Scopolamine Butylbromide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Scopolamine Butylbromide is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Scopolamine Butylbromide is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Scopolamine Butylbromide include Abbott Laboratories, AdvaCare Pharma, AS Kalceks, AUSMED, Boehringer Ingelheim, Medsurge Healthcare, Pharma Cure Laboratories, Chengdu First Pharmaceutical and Jiangsu Hengrui Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Scopolamine Butylbromide market in terms of revenue (US$ million) and, where applicable, sales volume (L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/L) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Scopolamine Butylbromide Market by Company
Abbott Laboratories
AdvaCare Pharma
AS Kalceks
AUSMED
Boehringer Ingelheim
Medsurge Healthcare
Pharma Cure Laboratories
Chengdu First Pharmaceutical
Jiangsu Hengrui Medicine
North China Pharmaceutical Group
Qilu Pharmaceutical
Sanofi
Shanghai Shangyao First Bio-pharmaceutical
Sichuan Medco Huakang Pharmaceutical
Wepon
Yabao Pharmaceutical Group
Scopolamine Butylbromide Segment by Type
1ml:20mg
2ml:40mg
Scopolamine Butylbromide Segment by Application
Biliary Tract Spasm
Urinary Tract Spasm
Gastrointestinal Spasm
Scopolamine Butylbromide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Scopolamine Butylbromide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Scopolamine Butylbromide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Scopolamine Butylbromide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Scopolamine Butylbromide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Scopolamine Butylbromide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Scopolamine Butylbromide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 1ml:20mg
- 2ml:40mg
Applications
- Biliary Tract Spasm
- Urinary Tract Spasm
- Gastrointestinal Spasm
Companies covered
- Abbott Laboratories
- AdvaCare Pharma
- AS Kalceks
- AUSMED
- Boehringer Ingelheim
- Medsurge Healthcare
- Pharma Cure Laboratories
- Chengdu First Pharmaceutical
- Jiangsu Hengrui Medicine
- North China Pharmaceutical Group
- Qilu Pharmaceutical
- Sanofi
- Shanghai Shangyao First Bio-pharmaceutical
- Sichuan Medco Huakang Pharmaceutical
- Wepon
- Yabao Pharmaceutical Group
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Scopolamine Butylbromide Market Size (2021-2032)
- 2.2.2 Global Scopolamine Butylbromide Sales (2021-2032)
- 2.2.3 Global Scopolamine Butylbromide Market Average Price (2021-2032)
- 2.3 Scopolamine Butylbromide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 1ml:20mg
- 2.3.3 2ml:40mg
- 2.4 Scopolamine Butylbromide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Biliary Tract Spasm
- 2.4.3 Urinary Tract Spasm
- 2.4.4 Gastrointestinal Spasm
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Scopolamine Butylbromide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Scopolamine Butylbromide Sales (L) of Manufacturers (2021-2026)
- 3.3 Global Scopolamine Butylbromide Revenue of Manufacturers (2021-2026)
- 3.4 Global Scopolamine Butylbromide Average Price by Manufacturers (2021-2026)
- 3.5 Global Scopolamine Butylbromide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Scopolamine Butylbromide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Scopolamine Butylbromide, Product Type & Application
- 3.8 Global Manufacturers of Scopolamine Butylbromide, Established Date
- 3.9 Global Scopolamine Butylbromide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott Laboratories
- 4.1.1 Abbott Laboratories Company Information
- 4.1.2 Abbott Laboratories Business Overview
- 4.1.3 Abbott Laboratories Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Laboratories Scopolamine Butylbromide Product Portfolio
- 4.1.5 Abbott Laboratories Recent Developments
- 4.2 AdvaCare Pharma
- 4.2.1 AdvaCare Pharma Company Information
- 4.2.2 AdvaCare Pharma Business Overview
- 4.2.3 AdvaCare Pharma Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AdvaCare Pharma Scopolamine Butylbromide Product Portfolio
- 4.2.5 AdvaCare Pharma Recent Developments
- 4.3 AS Kalceks
- 4.3.1 AS Kalceks Company Information
- 4.3.2 AS Kalceks Business Overview
- 4.3.3 AS Kalceks Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 AS Kalceks Scopolamine Butylbromide Product Portfolio
- 4.3.5 AS Kalceks Recent Developments
- 4.4 AUSMED
- 4.4.1 AUSMED Company Information
- 4.4.2 AUSMED Business Overview
- 4.4.3 AUSMED Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AUSMED Scopolamine Butylbromide Product Portfolio
- 4.4.5 AUSMED Recent Developments
- 4.5 Boehringer Ingelheim
- 4.5.1 Boehringer Ingelheim Company Information
- 4.5.2 Boehringer Ingelheim Business Overview
- 4.5.3 Boehringer Ingelheim Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Boehringer Ingelheim Scopolamine Butylbromide Product Portfolio
- 4.5.5 Boehringer Ingelheim Recent Developments
- 4.6 Medsurge Healthcare
- 4.6.1 Medsurge Healthcare Company Information
- 4.6.2 Medsurge Healthcare Business Overview
- 4.6.3 Medsurge Healthcare Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Medsurge Healthcare Scopolamine Butylbromide Product Portfolio
- 4.6.5 Medsurge Healthcare Recent Developments
- 4.7 Pharma Cure Laboratories
- 4.7.1 Pharma Cure Laboratories Company Information
- 4.7.2 Pharma Cure Laboratories Business Overview
- 4.7.3 Pharma Cure Laboratories Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pharma Cure Laboratories Scopolamine Butylbromide Product Portfolio
- 4.7.5 Pharma Cure Laboratories Recent Developments
- 4.8 Chengdu First Pharmaceutical
- 4.8.1 Chengdu First Pharmaceutical Company Information
- 4.8.2 Chengdu First Pharmaceutical Business Overview
- 4.8.3 Chengdu First Pharmaceutical Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Chengdu First Pharmaceutical Scopolamine Butylbromide Product Portfolio
- 4.8.5 Chengdu First Pharmaceutical Recent Developments
- 4.9 Jiangsu Hengrui Medicine
- 4.9.1 Jiangsu Hengrui Medicine Company Information
- 4.9.2 Jiangsu Hengrui Medicine Business Overview
- 4.9.3 Jiangsu Hengrui Medicine Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Jiangsu Hengrui Medicine Scopolamine Butylbromide Product Portfolio
- 4.9.5 Jiangsu Hengrui Medicine Recent Developments
- 4.10 North China Pharmaceutical Group
- 4.10.1 North China Pharmaceutical Group Company Information
- 4.10.2 North China Pharmaceutical Group Business Overview
- 4.10.3 North China Pharmaceutical Group Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 North China Pharmaceutical Group Scopolamine Butylbromide Product Portfolio
- 4.10.5 North China Pharmaceutical Group Recent Developments
- 4.11 Qilu Pharmaceutical
- 4.11.1 Qilu Pharmaceutical Company Information
- 4.11.2 Qilu Pharmaceutical Business Overview
- 4.11.3 Qilu Pharmaceutical Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Qilu Pharmaceutical Scopolamine Butylbromide Product Portfolio
- 4.11.5 Qilu Pharmaceutical Recent Developments
- 4.12 Sanofi
- 4.12.1 Sanofi Company Information
- 4.12.2 Sanofi Business Overview
- 4.12.3 Sanofi Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Sanofi Scopolamine Butylbromide Product Portfolio
- 4.12.5 Sanofi Recent Developments
- 4.13 Shanghai Shangyao First Bio-pharmaceutical
- 4.13.1 Shanghai Shangyao First Bio-pharmaceutical Company Information
- 4.13.2 Shanghai Shangyao First Bio-pharmaceutical Business Overview
- 4.13.3 Shanghai Shangyao First Bio-pharmaceutical Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Shanghai Shangyao First Bio-pharmaceutical Scopolamine Butylbromide Product Portfolio
- 4.13.5 Shanghai Shangyao First Bio-pharmaceutical Recent Developments
- 4.14 Sichuan Medco Huakang Pharmaceutical
- 4.14.1 Sichuan Medco Huakang Pharmaceutical Company Information
- 4.14.2 Sichuan Medco Huakang Pharmaceutical Business Overview
- 4.14.3 Sichuan Medco Huakang Pharmaceutical Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Sichuan Medco Huakang Pharmaceutical Scopolamine Butylbromide Product Portfolio
- 4.14.5 Sichuan Medco Huakang Pharmaceutical Recent Developments
- 4.15 Wepon
- 4.15.1 Wepon Company Information
- 4.15.2 Wepon Business Overview
- 4.15.3 Wepon Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Wepon Scopolamine Butylbromide Product Portfolio
- 4.15.5 Wepon Recent Developments
- 4.16 Yabao Pharmaceutical Group
- 4.16.1 Yabao Pharmaceutical Group Company Information
- 4.16.2 Yabao Pharmaceutical Group Business Overview
- 4.16.3 Yabao Pharmaceutical Group Scopolamine Butylbromide Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Yabao Pharmaceutical Group Scopolamine Butylbromide Product Portfolio
- 4.16.5 Yabao Pharmaceutical Group Recent Developments
5 Global Scopolamine Butylbromide Market Scenario by Region
- 5.1 Global Scopolamine Butylbromide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Scopolamine Butylbromide Sales by Region: 2021-2032
- 5.2.1 Global Scopolamine Butylbromide Sales by Region: 2021-2026
- 5.2.2 Global Scopolamine Butylbromide Sales by Region: 2027-2032
- 5.3 Global Scopolamine Butylbromide Revenue by Region: 2021-2032
- 5.3.1 Global Scopolamine Butylbromide Revenue by Region: 2021-2026
- 5.3.2 Global Scopolamine Butylbromide Revenue by Region: 2027-2032
- 5.4 North America Scopolamine Butylbromide Market Facts & Figures by Country
- 5.4.1 North America Scopolamine Butylbromide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Scopolamine Butylbromide Sales by Country (2021-2032)
- 5.4.3 North America Scopolamine Butylbromide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Scopolamine Butylbromide Market Facts & Figures by Country
- 5.5.1 Europe Scopolamine Butylbromide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Scopolamine Butylbromide Sales by Country (2021-2032)
- 5.5.3 Europe Scopolamine Butylbromide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Scopolamine Butylbromide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Scopolamine Butylbromide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Scopolamine Butylbromide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Scopolamine Butylbromide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Scopolamine Butylbromide Market Facts & Figures by Country
- 5.7.1 South America Scopolamine Butylbromide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Scopolamine Butylbromide Sales by Country (2021-2032)
- 5.7.3 South America Scopolamine Butylbromide Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Scopolamine Butylbromide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Scopolamine Butylbromide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Scopolamine Butylbromide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Scopolamine Butylbromide Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Scopolamine Butylbromide Sales by Type (2021-2032)
- 6.1.1 Global Scopolamine Butylbromide Sales by Type (2021-2032) & (L)
- 6.1.2 Global Scopolamine Butylbromide Sales Market Share by Type (2021-2032)
- 6.2 Global Scopolamine Butylbromide Revenue by Type (2021-2032)
- 6.2.1 Global Scopolamine Butylbromide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Scopolamine Butylbromide Revenue Market Share by Type (2021-2032)
- 6.3 Global Scopolamine Butylbromide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Scopolamine Butylbromide Sales by Application (2021-2032)
- 7.1.1 Global Scopolamine Butylbromide Sales by Application (2021-2032) & (L)
- 7.1.2 Global Scopolamine Butylbromide Sales Market Share by Application (2021-2032)
- 7.2 Global Scopolamine Butylbromide Revenue by Application (2021-2032)
- 7.2.1 Global Scopolamine Butylbromide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Scopolamine Butylbromide Revenue Market Share by Application (2021-2032)
- 7.3 Global Scopolamine Butylbromide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Scopolamine Butylbromide Value Chain Analysis
- 8.1.1 Scopolamine Butylbromide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Scopolamine Butylbromide Production Mode & Process
- 8.2 Scopolamine Butylbromide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Scopolamine Butylbromide Distributors
- 8.2.3 Scopolamine Butylbromide Customers
9 Global Scopolamine Butylbromide Analyzing Market Dynamics
- 9.1 Scopolamine Butylbromide Industry Trends
- 9.2 Scopolamine Butylbromide Industry Drivers
- 9.3 Scopolamine Butylbromide Industry Opportunities and Challenges
- 9.4 Scopolamine Butylbromide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst